



Eligibility Rules, Terms, and Conditions: Present this card to your pharmacist along with your insurance card and a valid prescription for Fanapt. Eligible patients may pay as little as \$0 copay per month for Fanapt. Offer valid for up to 12 uses within a calendar year. A valid Prescriber ID# is required on the prescription.

This offer is valid in the United States and Puerto Rico. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare or other federal or state health programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. Patients are not eligible if they are under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. Program expires 12/31/2025. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law, taxed, or restricted. Vanda Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice at any time.





FAN0072V13

01/25

FANAPT® SAVINGS CARD

Eligibility Rules, Terms, and Conditions: Present this card to your pharmacist along with your insurance card and a valid prescription for Fanapt[®]. Eligible patients may pay as little ats \$0 copay per month for Fanapt.

Offer valid for up to 12 uses within a calendar year. A valid Prescriber ID# is required on the prescription.

This offer is valid in the United States and Puerto Rico. Offer not valid for prescriptions reimbursed under Medicaid, a Medicare drug benefit plan, Tricare or other federal or state health programs (such as medical assistance programs). If the patient is eligible for drug benefits under any such program, the patient cannot use this offer. By using this offer, the patient certifies that he or she will comply with any terms of his or her health insurance contract requiring notification to his or her payer of the existence and/or value of this offer. Patients are not eligible if they are under 18 years of age. It is illegal to (or offer to) sell, purchase, or trade this offer. Program expires 12/31/2025. This offer is not transferable and is limited to one offer per person. Not valid if reproduced. Void where prohibited by law, taxed, or restricted. Vanda Pharmaceuticals reserves the right to rescind, revoke or amend this offer without notice at any time.

Patient instructions: Present this card, along with your prescription, to a participating pharmacy to save on out-of-pocket expenses for a Fanapt® prescription.

Consumer questions should be directed to 1-866-318-1969.

Pharmacy Instructions for Insured Patients: Submit this claim to the patient's prescription insurance first, then submit a secondary claim to CapitalRx under BIN: 610852/PCN: 2001 as a Secondary Payer COB [coordination of benefits] using Other Coverage Code 8. The patient amount submitted will be reduced by up to \$200.

Pharmacy Instructions for Cash Patients: Submit this claim to CapitalRx under BIN: 610852/PCN: 2001 as a Primary Payer COB [coordination of benefits] using Other Coverage Code 0 or 1. The patient amount submitted will be reduced by up to \$200.

Valid Other Coverage Code required. For any questions regarding processing, please call the Help Desk at 1-866-318-1969.

Fanapt® (iloperidone) tablets: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg Please click here for Important Product Information, including Boxed WARNING.

VANDA and FANAPT are registered trademarks of Vanda Pharmaceuticals Inc. in the United States and other countries. ©2025 Vanda Pharmaceuticals Inc. All rights reserved. FAN0072V13 01/25



INDICATION

Fanapt® (iloperidone) is a prescription medication used for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.

IMPORTANT SAFETY INFORMATION

WARNING: Elderly patients with psychosis related to dementia (having lost touch with reality due to memory loss and experiencing a decline in day-to-day functioning) who are treated with antipsychotic medications are at an increased risk of death compared to patients treated with a placebo. Fanapt® is not approved for use in people with dementia-related psychosis.

Patients should not use Fanapt® if they have a known allergy to Fanapt® or its ingredients. Allergic reactions, including anaphylaxis, rapid swelling of the skin (angioedema), and other symptoms of allergy (e.g., throat tightness; swelling of the throat, face, lips, mouth and tongue; hives; rash; and itching) have been reported.

An increased risk of stroke has been reported in clinical studies of elderly people with dementia-related psychosis. Fanapt® is not approved for use in people with dementia-related psychosis.

Fanapt® may change your heart rhythm (meaning there is more time between heartbeats). Heart rhythm changes have occurred in patients taking Fanapt® and are a risk factor for serious, even life-threatening medical issues. You should tell your healthcare provider if you have or have had heart problems. Contact your healthcare provider right away if you feel faint or have unpleasant feelings of irregular or forceful heartbeats as any of these feelings could be a sign of a rare, but serious side effect that could be fatal. You should not use Fanapt® with other drugs that are known to cause these same heart rhythm issues.

Tell your healthcare provider if you have some or all of the following symptoms; very high fever, rigid muscles, shaking, confusion, sweating or increased heart rate and blood pressure. These may be signs of a condition called neuroleptic malignant syndrome (NMS), a rare but serious side effect that could be fatal. This may happen with Fanapt® or drugs like it.

Abnormal or uncontrollable movements of the face, tongue, or other parts of the body may be signs of a serious condition called tardive dyskinesia (TD), which could become permanent. The chance of this condition going away decreases, depending on how long and how much medication has been taken. Tell your healthcare provider if you have body movements you can't control.

Fanapt® and medicines like it have been associated with metabolic changes (high blood sugar, high cholesterol and triglycerides, and weight gain) that can increase

cardiovascular/cerebrovascular risks. Increases in blood sugar levels (hyperglycemia), which in some cases can be serious and associated with coma or death, have been reported in patients taking Fanapt® and medicines like it. Changes in cholesterol and triglycerides have been seen in patients taking Fanapt® and medicines like it. Some patients may gain weight while taking Fanapt®. Your healthcare provider should check your blood sugar, fat levels, and weight before you start and regularly while you take Fanapt®.

Tell your healthcare provider about any medical conditions that you have, including problems with your liver. Fanapt® is not recommended for patients with severe liver problems.

Tell your healthcare provider if you have a history of or have a condition that may increase your risk for seizures before you begin taking Fanapt®.

Light-headedness or faintness caused by a sudden change in heart rate and blood pressure when rising quickly from a sitting or lying position (orthostatic hypotension) has been reported with Fanapt®. This condition is most common when you start therapy, when restarting treatment, or when the dose of Fanapt® is increased. You should consult your healthcare provider if you have or have had heart problems or conditions that lead to these sudden changes since Fanapt® should be used with caution in these patients.

Fanapt® may increase the risk of falls, which could cause fractures or other injuries.

Decreases in infection-fighting white blood cells (WBCs) have been reported in some patients taking antipsychotic agents. Patients with a preexisting history of low WBC count or who have experienced a low WBC count due to drug therapy should have their blood tested and monitored during the first few months of therapy. Some (including fatal) cases of agranulocytosis, a serious decrease in specific types of WBCs called neutrophils or granulocytes, have been reported in drugs like Fanapt®.

Fanapt® can increase the level of the hormone prolactin. Tell your healthcare provider if you experience breast enlargement, breast pain, or breast discharge, abnormal menstrual cycles in females or impotence in males. If elevated levels of prolactin persist, this may lead to bone loss.

Medicines like Fanapt® can impact your body's ability to reduce your body temperature. You should avoid overheating and dehydration.

Fanapt[®] and medicines like it have been associated with swallowing problems

(dysphagia). If you have or have had swallowing problems, you should tell your healthcare provider.

For males, in the rare event you have a painful or prolonged erection (priapism), lasting 4 or more hours, stop using Fanapt® and seek immediate medical attention.

Fanapt® and medicines like it can affect your judgment, thinking, or motor skills. You should not drive or operate hazardous machinery, including automobiles, until you know how Fanapt® affects you.

A condition called intraoperative floppy iris syndrome has been observed in some patients taking drugs like FANAPT®. Please tell your healthcare provider if you take or have taken Fanapt® before cataract or other eye surgeries.

The most common side effects for Fanapt® versus placebo in patients with schizophrenia were dizziness, dry mouth, feeling unusually tired or sleepy, stuffy nose, feeling faint/light-headed when standing quickly, racing heartbeat, and weight gain. The most common side effects for Fanapt® versus placebo in a clinical study of patients with bipolar I disorder were racing heartbeat, dizziness, dry mouth, increase in liver enzymes, stuffy nose, weight gain, low blood pressure, and feeling unusually tired or sleepy. Compared to placebo, the average weight gain in clinical studies in schizophrenia lasting 4 to 6 weeks was 6 pounds, and in a clinical study of patients with bipolar I disorder over 4 weeks was 7 pounds. If you experience any of these symptoms, talk with your healthcare provider.

When taking Fanapt®, you should avoid drinking alcohol, and you should not breastfeed.

You should notify your healthcare provider if you become pregnant or intend to become pregnant while taking Fanapt®.

Tell your healthcare provider about all prescription and non-prescription medicines and supplements you are taking. Some medications may interact with Fanapt®.

To access the full <u>Prescribing Information</u> including BOXED WARNING, visit <u>www.Fanapt.com</u>.

You are encouraged to report negative side www.fda.gov/medwatch, or call 1-800-FDA-1088.

To learn more, visit www.FANAPT.com

VANDA and FANAPT are registered trademarks of Vanda Pharmaceuticals Inc. in the United States and other countries.

©2025 Vanda Pharmaceuticals Inc. All rights reserved. FAN0072V13 01/25